Market Highlights
UTI drugs are used for the treatment of urinary tract
infection caused by bacterial or fungal infections. World Health Organization
(WHO) estimates that approximately 50 % of women have UTI at some point in
their lives resulting in more than $1 million hospitalizations per year. WHO
estimates the cost of UTI infections to be annually greater than $1 billion. It
has further been stated that chances of boys being diagnosed with UTI is 1%
while chances of girls being diagnosed with UTI is 3 to 8%. The Middle East and
Africa UTI drugs market is growing due to factors such as catheter associated
UTI, hospital borne infections (nosocomial infections), child birth, old age,
obesity, growing health awareness especially about women health etc. On the
other hand market constraints includes excellent efficacy of present
antibiotics specially quinolones, growing drug resistance, unmet clinical
needs, increasing incidence of chronic diseases etc. However, the rise of drug
resistance has created the need for novel acting antibiotic. The future of UTI
treatment seems to be development of biologics with greater market development
especially with respect to poorly growing African market. The loss of patents,
weakening developed pipelines and poor expenditure on health in African region
had further constrained the market growth.
Request For Sample Report: https://www.marketresearchfuture.com/sample_request/2540
The Middle East and Africa UTI drugs market has been
segmented into drug class which includes quinolones, aminoglycosides, β-lactam,
azoles and others. Among all these drug classes quinolones have the largest
market value due to their broad variety and excellent efficacy. The share of
aminoglycosides have been reduced by a small margin as this drug is resistance.
Thus the current trend in UTI treatment is combined drug regimen. The market
threat includes a form of substandard, counterfeit and spurious drugs have
emerged. However it has to be noted that a huge unmet need exists for these
drugs in the Middle East and African region.
Access Report Details @ https://www.marketresearchfuture.com/reports/mea-uti-drugs-market-2540
Key Players:
Major participants of this market are: Bayer AG, Novartis
AG, Pfizer Inc., F. Hoffmann-La Roche Ltd, AstraZeneca, Cipla Inc., Dr. Reddy’s
Laboratories Ltd. and others.
Middle East and Africa UTI Drugs market:
The Middle East and Africa UTI drugs market has been
evaluated to be growing market and is expected that the market will grow
moderately in the future. The Middle East and Africa UTI drugs market is
expected to grow with the CAGR of 4.35% during the forecast period. The growth
will primary be led by unmet medical needs and rising incomes of the
population.
Regional Analysis:
Depending on geographic region, UTI drugs market is
segmented into following countries: UAE, Egypt, Saudi Arabia, Kuwait, Qatar and
Oman; UAE is the largest market followed by Egypt. However the future market
will be led by poorly developed parts of Africa due to large unmet needs.
Market Segmentation:
Middle East and African UTI drugs market has been segmented
on the basis of drug class which comprises of quinolones, aminoglycosides,
β-lactam, azoles and others. On the basis of clinical Indications the market is
segmented into urethritis, cystitis and pyelonephritis. On the basis of end
users, market is segmented into hospitals and self-administered.
No comments:
Post a Comment